SS-31 Peptide Dose: What the Research Actually Shows

SS-31 (elamipretide, a mitochondria-targeting tetrapeptide also called Szeto-Schiller peptide 31, MTP-131, and Bendavia) has been studied at 0.05 mg/kg/hour intravenously and 40 mg/day subcutaneously in trials, but it is not FDA-approved and has no established consumer dose [1][2][3][4].

What is SS-31 peptide?

SS-31 is a small peptide studied for mitochondrial diseases and other conditions, but it is not FDA-approved for consumer wellness, fatigue, recovery, or longevity use [4]. Its international nonproprietary name is elamipretide; older names include Szeto-Schiller peptide 31, MTP-131, and Bendavia [1][5].

SS-31 belongs to a group often called mitochondrial peptides because it is designed to concentrate near the inner mitochondrial membrane, where cells make much of their ATP, or usable energy [5][6]. Research interest is highest in rare mitochondrial disorders such as primary mitochondrial myopathy and Barth syndrome, but trial results have been mixed, adverse events were reported, and individual results vary [2][3][7].

Stealth BioTherapeutics has studied elamipretide in several clinical programs, including primary mitochondrial myopathy, Barth syndrome, and ophthalmic mitochondrial disease research [2][3][7][8]. These studies do not establish an over-the-counter or self-directed dose, and subcutaneous studies reported adverse events, especially injection-site reactions [2][3][7].

How does SS-31 work in the body?

SS-31 appears to interact with cardiolipin, a fat-like molecule in the inner mitochondrial membrane, and this mechanism has been studied for effects on cytochrome c, the electron transport chain, ATP production, and reactive oxygen species over multiple preclinical and clinical programs [5][6]. The key idea is mitochondrial support under study, not a proven effect for fatigue, aging, or disease prevention.

In lab and animal research, SS peptides have been investigated for mitochondrial swelling, oxidative stress, and the mitochondrial permeability transition pore, a channel involved in cell injury under stress [5][9]. These findings help explain why researchers study SS-31, but lab and animal results do not prove benefit in humans and do not remove safety concerns.

Human trials are more cautious. In primary mitochondrial myopathy studies, researchers measured walking distance, fatigue scores, and patient-reported function, while also tracking adverse events such as injection-site reactions, nausea, headache, and dizziness [2][3].

What dose of SS-31 has been used in research?

Elamipretide research has used different routes and dose levels depending on the condition studied, including 0.05 mg/kg/hour intravenously in acute heart-attack research and 40 mg/day subcutaneously in primary mitochondrial myopathy research [1][2][3]. These are study-attributed doses, not instructions for personal use.

Intravenous elamipretide dosing in clinical trials

In the EMBRACE-STEMI trial, patients with ST-elevation myocardial infarction received elamipretide at 0.05 mg/kg/hour by intravenous infusion after primary percutaneous coronary intervention; the trial did not show a significant reduction in infarct size compared with placebo, and adverse events were monitored as part of the study [1].

Subcutaneous elamipretide dosing in clinical trials

In primary mitochondrial myopathy research, Karaa and colleagues studied elamipretide by subcutaneous injection, including a 40 mg/day regimen in later trials; these studies evaluated walking and fatigue outcomes and also reported safety findings, with injection-site reactions commonly seen [2][3].

In Barth syndrome research, elamipretide 40 mg/day by subcutaneous injection was studied in a small randomized withdrawal trial; the study assessed exercise and functional outcomes, and adverse events such as injection-site reactions were part of the safety review [7].

How is SS-31 dosed in compounding-based wellness use?

Compounded SS-31 via 503A pharmacy may be discussed in some wellness settings, but SS-31 is not FDA-approved for longevity, energy, recovery, fatigue, or mitochondrial optimization, and no standard consumer dose or cycle length has been established [4]. A licensed prescriber must decide whether any compounded use is appropriate after reviewing medical history, medicines, pregnancy status, and risks.

Online protocols may list starting ranges, body-weight charts, or goal-based schedules for energy, recovery, or longevity. This article does not provide those protocols because they are not FDA-approved instructions and may not be supported by clinical trial evidence for those goals [4].

A clinician considering off-label SS-31 would review the route, concentration, sterile handling, kidney and liver history, heart history, pregnancy or breastfeeding status, active cancer history, autoimmune disease, and current medications. Those factors matter because compounded peptide use can carry contamination, dose-accuracy, and side-effect risks if it is not prescribed and dispensed correctly [4].

How do you inject SS-31?

SS-31 has been studied by subcutaneous injection in primary mitochondrial myopathy trials and by intravenous infusion in acute cardiac research, but there is no FDA-approved self-injection protocol for consumers [1][2][3]. In studies using subcutaneous injection, the medicine was placed into the fatty layer under the skin under a defined research protocol [2][3].

If prescribed, injection training should come from the clinician and dispensing pharmacy. In studies of daily subcutaneous elamipretide, injection-site reactions were common, so sterile supplies, site rotation, and proper disposal are safety topics for a prescriber or pharmacist to review [2][3].

A vial with unclear labeling, no pharmacy information, visible particles, broken sterility, or no prescriber oversight should raise concern. Sterile compounded injections should come from licensed pharmacies that follow applicable compounding rules and quality controls [4].

What results should you expect from SS-31, and when?

Elamipretide has shown mixed human results, and there is no proven timeline for wellness, energy, recovery, or longevity outcomes over any consumer cycle length [1][2][3][7]. Trial results should not be read as a guarantee; individual results vary, and adverse events were tracked in the same studies [1][2][3][7].

In primary mitochondrial myopathy research, investigators measured outcomes such as 6-minute walk distance, fatigue scores, and patient-reported function over defined study periods, while also tracking adverse events [2][3]. Some endpoints suggested possible benefit in selected analyses, while other endpoints did not clearly separate from placebo [2][3].

In the EMBRACE-STEMI heart-attack trial, elamipretide did not significantly reduce infarct size compared with placebo, despite a biologic rationale related to mitochondrial injury [1]. That is why SS-31 should be described as investigated for mitochondrial biology, not as proven to improve energy or prevent disease.

What are the side effects and safety considerations for SS-31?

SS-31 safety data come mainly from controlled research settings, not broad consumer wellness use, and reported events were followed during clinical trial monitoring [1][2][3][7]. Reported side effects include injection-site reactions with subcutaneous dosing, as well as symptoms such as nausea, headache, dizziness, and other adverse events tracked in trials [2][3].

• Avoid self-sourcing or self-mixing SS-31 because sterility and dose accuracy matter for injectable products [4].
• Tell a clinician about heart disease, kidney disease, liver disease, neurologic disease, autoimmune disease, cancer history, pregnancy, breastfeeding, and all medicines before considering any peptide.
• Seek urgent care for severe allergic symptoms, chest pain, fainting, severe shortness of breath, or signs of infection at an injection site.
• Do not assume that “mitochondrial support” means risk-free; trial settings include screening, monitoring, adverse-event reporting, and defined stopping rules [1][2][3].

People with primary mitochondrial disease, cardiomyopathy, arrhythmia, severe kidney or liver disease, pregnancy, or complex medication lists need extra caution. Eligibility depends on a clinician’s evaluation, not an online dose chart.

How do you get SS-31 safely and legally?

SS-31 is not an FDA-approved drug for consumer wellness use, so safe access starts with a licensed clinician who can explain whether any legal, compounded, or research-based path is appropriate under 503A rules [4]. A 503A compounding pharmacy prepares patient-specific prescriptions when allowed under federal and state rules, but compounded products are not FDA-approved in the same way as commercial drugs [4].

If SS-31 is being considered, ask whether the pharmacy is licensed, whether sterility testing is performed, whether the prescription is patient-specific, and whether the prescriber will monitor side effects. Chia is one telehealth option where a clinician can review eligibility for compounded longevity peptides when legally available and clinically appropriate.

How does SS-31 compare with other mitochondrial peptides?

SS-31 is best known for targeting cardiolipin near the inner mitochondrial membrane, while peptides such as MOTS-c and SBT-272 are discussed in different mitochondrial research contexts [5][6][11]. None of these compounds is FDA-approved for general wellness or longevity use, and each has different evidence and safety gaps.

What peptides stack well with SS-31?

SS-31 is sometimes commonly combined in clinical and research practice discussions with other longevity peptides, but there are no strong combination-specific trials that prove added benefit or establish a safe combined protocol. Because SS-31 is not FDA-approved for wellness use, any stack should be treated as experimental and clinician-supervised [4].

• SS-31 + MOTS-c: the rationale is that SS-31 is studied for cardiolipin and inner-membrane mitochondrial biology, while MOTS-c is studied for metabolic signaling; the caveat is limited human evidence and no FDA-approved combination use [5][11].
• SS-31 + NAD+: the rationale is that both relate to cellular energy pathways, though through different mechanisms; the caveat is that combined use may increase side-effect uncertainty and should not be self-directed.
• SS-31 + GHK-Cu: the rationale is that some clinicians discuss mitochondrial support alongside skin and tissue-repair peptides; the caveat is that combination-specific safety data are lacking, and sterile injection quality matters.

No existing Chia internal-link targets were provided for this article brief. Before publication, internal links should be filled from the Chia article inventory for related peptide pages such as MOTS-c, NAD+, GHK-Cu, and compounded peptide safety.

Keep reading

Longevity Peptides

SS-31 Peptide (Elamipretide): What It Is, How It Works, and What the Research Shows

Longevity Peptides

MOTS-c Peptide: What It Is, How It Works, and How to Get It

Peptides

USA Peptides: What “Research-Only” Means and Legal Ways to Access Peptides